

## BIostatistics Core Facility

### PUBLICATIONS (2013-2016) (M denotes methods paper)

#### Dignam

Labby ZE, Nowak AK, **Dignam JJ**, Straus C, Kindler HL, Armato SG 3<sup>rd</sup>. Disease volumes as a marker for patient response in malignant pleural mesothelioma, *Annals of Oncology*, 24:999-1005, 2013

Labby ZE, Armato SG 3<sup>rd</sup>, Kindler H, **Dignam JJ**, Straus C, Kindler HL, Nowak AK. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. *Journal of Thoracic Oncology*, 8:478-486, 2013

Argos M, Rahman M, Parvez F, **Dignam J**, Islam T, Quasem I, Kumar Hore S, Talat Haider A, Hossain Z, Islam Patwary T, Rakibuz-Zaman M, Sarwar G, La Porte P, Harjes J, Anton K, Kibriya MG, Jasmine F, Khan R, Kamal M, Shea CR, Yunus M, Baron JA, Ahsan H. Baseline comorbidities in a skin cancer prevention trial in Bangladesh. *European Journal of Clinical Investigation*, 43:579-588, 2013

Huo N, Hong S, Wang W, Olopade OI, **Dignam JJ**, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. *Journal of the National Cancer Institute*, 105:1365-1372, 2013

(M) Sene M, Taylor JMG, **Dignam JJ**, Jacqmin-Gadda H, Proust-Lima C. Personalized dynamic prediction of prostate cancer recurrence according to the initiation of a second treatment: development and validation. *Statistical Methods in Medical Research*, online May 20, 2014

(M) Lee M, **Dignam JJ**, Han J. Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure. *Statistics in Medicine*, 33:4605-4626 2014

(M) Yu M, Han B, **Dignam JJ**, Rathouz PJ. Bayesian approach for flexible modeling of semi-competing risks data. *Statistics in Medicine*, 33:5111-5125, 2014

(M) Korn EL, **Dignam JJ**, Freidlin B. Assessing treatment benefit with competing risks not affected by the randomized treatment. *Statistics in Medicine*, 34:265-280, 2015

(M) **Dignam JJ**, Karrison TG. Building firm foundations for therapy development (editorial). *Journal of the National Cancer Institute*, 107:3 2015

Polite B, Cipriano-Steffens T, Hlubocky F, **Dignam J**, Gehlert S, Ray M, Smith D, Undevia S, Sprague E, Olopade O, Daugherty C, Fitchett G, Gehlert S. An evaluation of psychosocial and belief differences in a diverse racial and socioeconomic cancer population. *Journal of Racial and Ethnic Disparities*, Mar 16, 2016. [Epub ahead of print]

(M) Ferrer L, Rondeau V, **Dignam J**, Pickles T, Jacqmin-Gadda H, Proust-Lima C. Joint modeling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer, *Statistics in Medicine*, 35:3933-3946, 2016

(M) Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, **Dignam JJ**. Comparison of fertility monitoring guidelines using completed oncology trials. *Clinical Trials*, Sept 1 [Epub ahead of print]

Smith GL, Ganz PA, Beckelman JE, Chmura SJ, **Dignam JJ**, Esftathiou JA, Jagsi R, Johnson PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Shih YT. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy forum workshop. Accepted, *International Journal of Radiation Oncology, Biology, and Physics*, Published online: November 8, 2016

**Gao** (arrived at institution, 2015)

Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, **Gao G**, **Karrison T**, Lingen M, Nakamura Y, Hamamoto R. (2016) WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. *Oncotarget*. doi:10.18632/oncotarget.9897.

**Hedeker** (arrived at institution, 2014)

(M) Piasecki, T.M., Trela, C.J., **Hedeker, D.**, & Mermelstein, R.J. (2014). Smoking antecedents: Separating between- and within-person effects of tobacco dependence in a high-risk, multi-wave ecological momentary assessment investigation. *Nicotine and Tobacco Research*, 16, Supplement 2, S119-S126.

(M) Pugach O, **Hedeker D**, & Mermelstein RJ (2014). A bivariate mixed-effects location-scale model with application to ecological momentary assessment (EMA) data. *Health Services and Outcomes Research Methodology*, 14(4):194-212.

(M) Pugach O, **Hedeker D**, Richmond MJ, Sokolovsky A, & Mermelstein, RJ (2014). Modeling mood variation and covariation among adolescent smokers: Application of a bivariate location-scale mixed-effects model. *Nicotine and Tobacco Research*, 16, Supplement 2, S151-S158.

(M) Siddique J, Harel O, Crespi CM & **Hedeker D** (2014). Binary variable multiple-model multiple imputation to address missing data mechanism uncertainty: Application to a smoking cessation trial. *Statistics in Medicine*, 33(17), 3013-3028.

(M) Sokolovsky, A., Mermelstein, R.J., & **Hedeker, D.** (2014). Factors predicting compliance to ecological momentary assessment among adolescent smokers. *Nicotine and Tobacco Research*, 16(3), 351-358.

(M) **Hedeker D** (2015). Methods for multilevel ordinal data in prevention research. *Prevention Science*, 16:997-1006.

**Karrison**

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, **Karrison TG**, Ration MJ, Bies RR (2013). Estimation of renal cell carcinoma treatment effects from disease

progression modeling. *Clinical Pharmacology & Therapeutics* 93:345-351. PMID: PMC3791430

Sharma MR, **Karrison TG**, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EEW (2013). Evaluation of food effect on pharmacokinetics of vismodegib in advance solid tumor patients. *Clinical Cancer Research*, OnlineFirst April 3, 2013. PMID: PMC3674138

Ferguson BD, Liu R, Rolle CE, Tan Y-H C, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, **Karrison T**, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia, R (2013). The EphB4 receptor tyrosine kinase promotes lung cancer growth: A potential novel therapeutic target. *PLOS One* 8:1-16. PMID: PMC3699624

Geynisman DM, Zha Y, Kunnavakkam R, Aklilu M, Catenacci DV, Polite BN, Rosenbaum C, Namakydoust A, **Karrison T**, Gajewski TF, Kindler HL. A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. *J Immunother Cancer*. 2013 Jun 27;1:8. doi: 10.1186/2051-1426-1-8. eCollection 2013. PMID: PMC4019890.

Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL III, Hagemeister F, **Karrison T**, Smith SM (2013). A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. *Cancer* 119(9):1683-1689. PMID: PMC4332882

Catenacci DVT, Liao W-L, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao S-Y, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, **Karrison T**, Veenstra TD, Hembrough T, Burrows J (2014). Absolute quantitation of Met using mass spectrometry for clinical application: Assay precision, stability, and correlation with *MET* gene amplification in FFPE tumor tissue. *PLOS One* 9:1-14. PMID: PMC4077664

Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, **Karrison T**, Maitland ML, Salgia R, Ratain MJ (2014). Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the *UGT1A1* genotype of patients with cancer. *Journal of Clinical Oncology* 32:2328-2334. PMID: PMC4105486

Cohen EEW, **Karrison TG**, **Kocherginsky M**, Mueller J, Egan R, Huang CH, et al. (2014). Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. *Journal of Clinical Oncology* 32(25):2735-2743. PMID: PMC4876357

Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, **Karrison T**, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O (2014). Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. *Clin Cancer Res*. 20(2):490-8. PMID: PMC4310865

Arina A, Schreiber K, Binder DC, **Karrison TG**, Liu RB, Schreiber H (2014). Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. *Journal of Immunology* 192:1286-1293. PMID: PMC4084557

(M) Sharma MR, Gray E, Goldberg RM, Sargent DJ, **Karrison TG** (2014). Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. *Journal of Clinical Oncology* 33(1):36-41. PMID: PMC4268251

Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, **Karrison TG**, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR (2014). [Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib](#). *Clin Cancer Res*. 2015 Jan 15;21(2):365-72. doi: 10.1158/1078-0432.CCR-14-1683. Epub 2014 Nov 19. PubMed PMID: PMC4323272

Das LC, **Karrison TG**, Witt ME, Muller C, Stenson K, Blair EA, Cohen EEW, Seiwert TY, Haraf DJ, Vokes EE (2015). Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. *Annals of Oncology* 26:198-205

O'Donnell PH, Karovic S, **Karrison TG**, Janisch L, Levine MR, Harris PJ et al. (2015). Serum c-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide. *Clinical Cancer Research* 21:5092-5098. PMID: PMC4677671

Catenacci DVT, Junttila MR, **Karrison T**, Bahary N, Horiba MN, Nattam SR et al. (2015). Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. *J Clin Oncol* 33:4284-4292. PMID: PMC4678179

Yao K, Liederbach E, Lutfi W, Wang C-H, Hou N, **Karrison T**, Huo D (2015). Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. *Jour Surgical Oncology* 112:809-814.

Odenike O, Halpern A, Godley LA, Madzo J, **Karrison T**, Green M, Fulton N, Mattison RJ, Yee KWL, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W (2015). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. *Investigational New Drugs* 33:371-379. PMID: PMC4390421

Posadas EM, Ahmed RS, **Karrison T**, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM (2016). Saracatinib as a metastatic inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago phase 2 consortium and DOD/PCF prostate cancer clinical trials consortium study. *The Prostate* 76:286-293. PMID: PMC4904773

Wong SJ, **Karrison T**, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak ARA, Roberts JD, Vokes EE, Cohen EEW (2016). Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. *Annals of Oncology* 27:318-323. PMID: PMC4722891

Choudhury MJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, **Karrison T**, Stadler WM, Nakamura Y, O'Donnell PH (2016). Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. *Jour Clin Oncol* 34:1-7.

Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, **Karrison T**, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM (2016). Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, RIFAB, and ETF1, as well as the Wnt pathway, as potential targetes in del(5q) myeloid neoplasms. *Haematologica* 101:e232-e236. PMID: PMC5013937

Pearce SM, Pariser JJ, **Karrison T**, Patel SG, Eggener SE (2016). Comparison of perioperative and early oncologic outcomes between open and robotic assisted laparoscopic prostatectomy in a contemporary population based cohort. *The Journal of Oncology* 196:76-81.

Villaflor VM, Melotek JM, **Karrison TG**, Brisson RJ, Blair EA, Portugal L et al. (2016). Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. *Annals of Oncology* 27:908-913.

(M) **Karrison T** (2016). Versatile tests for comparing survival curves based on weighted logrank statistics. *The STATA Journal* 16:678-690.

Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, **Karrison T**, Stadler WM (2016). Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. *Clinical Genitourinary Cancer* Epub *in press*

Arina A, **Karrison T**, Galka E, Schreiber K, Weichselbaum RR, Schreiber H (2017). Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1-resistant tumors leading to tumor eradication. *Cancer Immunology Research*, epub, *in press*.

**Kocherginsky** (departed institution, April, 2016)

Tretiakova M, Antic T, Binder D, **Kocherginsky M**, Liao C, Taxy JB, Oto A. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. *Hum Pathol.* 2013;44(4):495-502.

Bissonnette ML, **Kocherginsky M**, Tretiakova M, Jimenez RE, Barkan GA, Mehta V, Sirintrapun SJ, Steinberg GD, White KP, Stricker T, Paner GP. The different morphologies of urachal adenocarcinoma do not discriminate genomically by micro-RNA expression profiling. *Hum Pathol.* 2013;44(8):1605-11.

Chen JL, Appelbaum DE, **Kocherginsky M**, Cowey CL, Rathmell WK, McDermott DF, Stadler WM. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. *Cancer Med.* 2013;2(4):545-52. PMID: 3799289.

Volden PA, Wonder EL, Skor MN, Carmean CM, Patel FN, Ye H, **Kocherginsky M**, McClintock MK, Brady MJ, Conzen SD. Chronic social isolation is associated with metabolic gene expression changes specific to mammary adipose tissue. *Cancer Prev*

Res (Phila). 2013;6(7):634-45. PMID: 3881320.

Bragelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, **Kocherginsky M**, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. *Oral Oncol*. 2013;49(6):525-33.

Muffly LS, Boulukos M, Swanson K, **Kocherginsky M**, Cerro PD, Schroeder L, Pape L, Extermann M, Van Besien K, Artz AS. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. *Biol Blood Marrow Transplant*. 2013;19(3):429-34.

Pekow J, Dougherty U, Huang Y, Gometz E, Nathanson J, Cohen G, Levy S, **Kocherginsky M**, Venu N, Westerhoff M, Hart J, Noffsinger AE, Hanauer SB, Hurst RD, Fichera A, Joseph LJ, Liu Q, Bissonnette M. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. *Inflamm Bowel Dis*. 2013;19(3):461-70. PMID: 3836269.

Vasanthakumar A, Lepore JB, Zegarek MH, **Kocherginsky M**, Singh M, Davis EM, Link PA, Anastasi J, Le Beau MM, Karpf AR, Godley LA. Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. *Blood*. 2013;121(11):2059-63. PMID: 3596965.

Skor MN, Wonder EL, **Kocherginsky M**, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. *Clin Cancer Res*. 2013;19(22):6163-72. PMID: 3860283.

Cohen EE, Ahmed O, **Kocherginsky M**, Shustakova G, Kistner-Griffin E, Salama JK, Yefremenko V, Novosad V. Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy. *Oral Oncol*. 2013;49(10):1025-31. PMID: 3797568.

Carlton DA, **Kocherginsky M**, Langerman AJ. A systematic review of the quality of randomized controlled trials in head and neck oncology surgery. *Laryngoscope*. 2014.

Armato SG, 3rd, Nowak AK, Francis RJ, **Kocherginsky M**, Byrne MJ. Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions. *J Thorac Oncol*. 2014;9(8):1187-94.

Muffly LS, **Kocherginsky M**, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. *Haematologica*. 2014;99(8):1373-9. PMID: 4116837.

Namm JP, Mueller J, **Kocherginsky M**, Kulkarni S. The Utility of Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma In Situ Suspicious for Microinvasion on Core Biopsy. *Ann Surg Oncol*. 2014.

Tretiakova M, Zynger DL, Luan C, Andeen NK, Finn LS, **Kocherginsky M**, Teh BT, Yang XJ. Glypican 3 overexpression in primary and metastatic Wilms tumors. *Virchows Arch*. 2015 Jan;466(1):67-76.

Stringer-Reasor EM, Baker GM, Skor MN, **Kocherginsky M**, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death

in high-grade serous ovarian carcinoma. *Gynecol Oncol*. 2015 Jun 24. doi: 10.1016/j.ygyno.2015.06.033.

Singh P, Brock CO, Volden PA, Hernandez K, Skor M, **Kocherginsky M**, Park JE, Brady MJ, Conzen SD. Glucocorticoid receptor ChIP-sequencing of subcutaneous fat reveals modulation of inflammatory pathways. *Obesity*. 2015 Sep 26. [Epub ahead of print]

D'Angelo CR, **Kocherginsky M**, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. *Leuk Lymphoma*. 2015 Dec 24:1-7. [Epub ahead of print]

Ezewuiro O, Grushko TA, **Kocherginsky M**, Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF, Romero IL. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. *PLoS One*. 2016 Jan 20;11(1):e0147145. doi: 10.1371/journal.pone.0147145. eCollection 2016. PMID: PMC4720394.

Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, **Kocherginsky M**, Conzen SD. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. *Horm Cancer*. 2016 Apr;7(2):114-26. doi: 10.1007/s12672-016-0251-8. Epub 2016 Feb 8. PMID: PMC4789079.

West DC, Pan D, Tonsing-Carter EY, Hernandez KM, Pierce CF, Styke SC, Bowie KR, Garcia TI, **Kocherginsky M**, Conzen SD. GR and ER co-activation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. *Mol Cancer Res*. 2016 May 2. pii: molcanres.0433.2015.

Meckel K, Li YC, Lim J, **Kocherginsky M**, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. *Am J Clin Nutr*. 2016 Jun 8. doi: 10.3945/ajcn.115.123786. PMID: 27281309.

Nanda R, Stringer-Reasor EM, Saha P, **Kocherginsky M**, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. *Springerplus*. 2016 Jun 30;5(1):947. doi: 10.1186/s40064-016-2457-1. eCollection 2016. PubMed PMID: 27386391; PubMed Central PMCID: PMC4929099.

Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, **Kocherginsky M**, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7. PubMed PMID: 27511844.

Chon WJ, Aggarwal N, **Kocherginsky M**, Kane B, Sutor J, Josephson MA. High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients. *Kidney*

Res Clin Pract. 2016 Sep;35(3):176-81. doi: 10.1016/j.krccp.2016.05.005. PubMed PMID: 27668162; PubMed Central PMCID: PMC5025461.

## Lee

(M) **Lee SM, Karrison TG**, Cox NJ, Im HK (2013). Quantitative allelic test—a fast test for very large association studies. *Genetic Epidemiology* 17:831-839.

Daniel V.T. Catenacci, Wei-Li Liao , Lei Zhao, Emma Whitcomb, Les Henderson, Emily ODay, Peng Xu, Sheeno Thyparambil, Kathleen Bengali, Jamar Uzzell, Marlene Darer, David Krizman, Fabiola Cecchi, Adele Blackler, John Hart, Shu-Yuan Xiao, **Sang Mee Lee**, Jon Burrows, and Todd Hembrough. Mass spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH. (2015) *Gastric Cancer*, 19(4), 1066-79.

Mark A. Applebaum, Tara O. Henderson, **Sang Mee Lee**, Navin Pinto, Samuel L. Volchenbom and Susan L. Cohn. Second Malignancies in Patients with Neuroblastoma: The Effects of Risk-Based Therapy. (2015) *Pediatric Blood & Cancer*, 62(1), 128-33

Susana R. Marino, **Sang Mee Lee**, T. Andrew Binkowski, Tao Wang, Michael Haagenson, Hai-Lin Wang, Martin Maiers, Stephen Spellman, Koen van Besien, Stephanie J. Lee, **Theodore Karrison**, and Andrew Artz. Identification of High- Risk Amino Acid Substitutions In Hematopoietic Cell Transplantation: A Challenging Task. (2016) *Bone Marrow Transplantation*, 51, 1342-1349

Mark A. Applebaum, Zalman Vaksman, **Sang Mee Lee**, Eric A. Hungate, Tara O. Henderson, Wendy B. London, Navin Pinto, Samuel L. Volchenbom, Julie R. Park, Arlene Naranjo, Barbara Hero, Andrew D. Pearson, Barbara Stranger, Susan L. Cohn and Sharon J. Diskin. Second Malignancies in Patients with Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project (2016) *In press*. *European Journal of Cancer*

## Watson (departed institution, November, 2016)

Oto A, Sethi I, Karczmar G, McNichols R, Ivancevic MK, Stadler WM, **Watson S**, Eggener S. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. *Radiology* 267:932-40, 2013.

Ferguson MK, **Watson S**, Johnson E, Vigneswaran WT. Predicted postoperative lung function is associated with all-cause long-term mortality after major lung resection for cancer. *Eur J Cardiothorac Surg* 45:660-4, 2014.

Ferguson MK, Im HK, **Watson S**, Johnson E, Wigfield CH, Vigneswaran WT. Association of body mass index and outcomes after major lung resection. *Eur J Cardiothorac Surg* 45:e94-9, 2014.

Williams T, Duraid H, **Watson S**, Durkin A, Todd K, Kindler HL, Vigneswaran WT. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an



Effective and Safe Cytoreductive Surgery in the Elderly. *Ann Thorac Surg* 100:1868-74, 2015.

Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, **Watson S**, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. *Cancer Lett* 359:269-74, 2015.

Wong AC, **Watson SP**, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). *Cancer* 122:2242-50, 2016.

Kircheva DY, Husain AN, **Watson S**, Kindler HL, Durkin A, Vigneswaran WT. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 49:1642-7, 2016.

Egger SE, Yousuf A, **Watson S**, Wang S, Oto A. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. *J Urol* 196:1670-1675, 2016.

Vigneswaran WT, Kircheva DY, Ananthanarayanan V, **Watson S**, Arif Q, Celauro AD, Kindler HL, Husain AN. Amount of Epithelioid Differentiation is a Predictor of Survival in Malignant Pleural Mesothelioma. *Ann Thorac Surg* , 2016 (Epub ahead of print).

### **Wroblewski**

Nathan PC, Daugherty CK, **Wroblewski KE**, Kigin ML, Stewart TV, Hlubocky FJ, Grunfeld E, Del Giudice ME, Ward LA, Galliher JM, Oeffinger KC, Henderson TO (2013). Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. *J Cancer Surviv* 7:275-82.

Bhatta SS, **Wroblewski KE**, Agarwal KL, Sit L, Cohen EE, Seiwert TY, **Karrison T**, Bakris GL, Ratain MJ, Vokes EE, Maitland ML (2013). Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. *Oncologist* 18:965-70.

Konda VJ, Meining A, Jamil LH, Giovannini M, Hwang JH, Wallace MB, Chang KJ, Siddiqui UD, Hart J, Lo SK, Saunders MD, Aslanian HR, **Wroblewski K**, Waxman I (2013). [A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance.](#) *Endoscopy* 45:1006-13.

Konda VJ, Cherkezyan L, Subramanian H, **Wroblewski K**, Damania D, Becker V, Gonzalez MH, Koons A, Goldberg M, Ferguson MK, Waxman I, Roy HK, Backman V (2013). Nanoscale markers of esophageal field carcinogenesis: potential implications for esophageal cancer screening. *Endoscopy* 45:983-8.

de Souza JA, Yap BJ, Hlubocky FJ, **Wroblewski K**, Ratain MJ, Cella D, Daugherty CK. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. *Cancer*. 2014 Oct 15;120(20):3245-53.

Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, **Wroblewski K**, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. *J Clin Invest*. 2014 Oct;124(10):4614-28.

Habis M, **Wroblewski K**, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. *PLoS One*. 2014 Aug 13;9(8):e104521.

Thomeas V, Chow S, Gutierrez JO, Karovic S, **Wroblewski K**, Kistner-Griffin E, **Karrison TG**, Maitland ML. Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors. *J Clin Pharmacol*. 2014 Jun;54(6):682-7.

Suh E, Daugherty CK, **Wroblewski K**, Lee H, Kigin ML, Rasinski KA, Ford JS, Tonorezos ES, Nathan PC, Oeffinger KC, Henderson TO. General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. *Ann Intern Med*. 2014 Jan 7;160(1):11-7.

Maitland ML, Levine MR, Lacouture ME, **Wroblewski KE**, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, **Karrison TG**, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. *BMC Cancer*. 2014 Jan 4;14:5.

Baron BW, Anastasi J, Bies J, Reddy PL, Joseph L, Thirman MJ, **Wroblewski K**, Wolff L, Baron JM. GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas. *Blood Cells Mol Dis*. 2014 Jan;52(1):68-75.

Kennedy V, Abramsohn E, Makelarski J, Barber R, **Wroblewski K**, Tenney M, Lee NK, Yamada SD, Lindau ST. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. *Gynecol Oncol*. 2015 Apr;137(1):119-24.

Muffly LS, Hlubocky FJ, Khan N, **Wroblewski K**, Breitenbach K, Gomez J, McNeer JL, Stock W, Daugherty CK. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. *Cancer*. 2016 Mar 15;122(6):954-61.

Reyes EE, Gillard M, Duggan R, **Wroblewski K**, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ, Griend DJ. Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. *J Transl Sci*. 2015 Jul;1(1).

Daly B, Hantel A, **Wroblewski K**, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. *J Oncol Pract*. 2016 Oct;12(10):e901-e911.